Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects

NCT07042204 | Completed

• 1 other identifier: A03011023OM
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.

Conditions

Furcation Defects

Outcome Measures

Primary Outcomes (1)

• The primary outcome will be the amount of bone fill vertically and horizontally obtained in the treatment of grade II furcation defects calculated from CBCT data in millimeters

  6 months follow up

Secondary Outcomes (4)

• the secondary outcomes include improvements (decrease)of probing depth in millimetres

  3 and 6 months follow up

• the secondary outcomes include improvements (decrease)of clinical attachment level loss in millimetres

  3 and 6 months follow up

• the secondary outcomes include improvements (decrease) of gingival recession measured in millimetres

  3 and 6 months follow up

• the secondary outcomes include improvements (decrease) of gingival bleeding index

  3 and 6 months follow up

Study Arms (3)

Group I

EXPERIMENTAL

10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.

Procedure: Group I (extended platelet-rich fibrin)

Group II

EXPERIMENTAL

10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).

Procedure: Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)

Group III

ACTIVE COMPARATOR

10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.

Procedure: Group III (bioactive glass nanoparticles and covered by a collagen membrane)

Interventions

Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin) PROCEDURE

bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)

Group II

Group III (bioactive glass nanoparticles and covered by a collagen membrane) PROCEDURE

bioactive glass nanoparticles and covered by a collagen membrane

Group III

Group I (extended platelet-rich fibrin) PROCEDURE

mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group

Group I

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Presence of Glickman's grade II furcation defects in molars probing depth (PD) ≥5 mm horizontal PD ≥3 mm.
• The patients are in good systemic health and had not undergone any periodontal surgery in the areas to be treated within the prior 12 months.

You may not qualify if:

• Smokers and tobacco chewers.
• Patients that take any medications within the past 6 months that could alter their periodontal status.
• pregnant or lactating females.
• Patients with known allergy to materials or drugs that will be used or prescribed in this study.

Sponsors & Collaborators

• Merna Nasser Mohamed Mostafa Ibrahim Elnahas: lead

Study Sites (1)

Mansoura University

Al Mansurah, 35516, Egypt

Location

MeSH Terms

Conditions

Furcation Defects

Condition Hierarchy (Ancestors)

Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases

Study Officials

• Merna N Elnahas, Master's degree

  Mansoura Unniversity

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: BDS, Clinical demonstrator, Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department

Study Record Dates

• First Submitted: June 18, 2025
• First Posted: June 27, 2025
• Study Start: January 3, 2024
• Primary Completion: June 3, 2025
• Study Completion: August 3, 2025
• Last Updated: January 13, 2026

Record last verified: 2026-01

Locations

EG (1)